

July 28, 2023

The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, 5th Floor,  
Plot No. C-1, G- Block,  
Bandra - Kurla Complex, Bandra (East)  
Mumbai – 400 051

BSE Limited  
Corporate Relationship Department  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai 400 001

Symbol: RPGLIFE

Scrip Code: 532983

Dear Sirs,

**Sub: Press Release - Financial Results**

Please find enclosed herewith a copy of press release with respect to Unaudited Financial Results of the Company for the quarter ended June 30, 2023.

Kindly take the above on record.

Thanking you,

Yours Sincerely,

For RPG Life Sciences Limited

**RAJESH**

**RAMESH**

**SHIRAMBEKAR**

Rajesh Shirambekar

Head – Legal & Company Secretary

Digitally signed by  
RAJESH RAMESH  
SHIRAMBEKAR  
Date: 2023.07.28 18:25:50  
+05'30'



Encl.: as above



**Q1 FY24 Revenue from operations grew by 15% Y-o-Y and 25% Q-o-Q.  
PBT grew by 19% Y-o-Y and 116% Q-o-Q with EBITDA margin expanding to 23.0%.**

**Mumbai, 28 July, 2023:** RPG Life Sciences Limited has announced its financial results for the quarter ended June 30, 2023.

Q1 FY24 Highlights	Y-o-Y Revenue from operations	Y-o-Y PBT
	Rs 147.78 crores – up from Rs 128.93 crores	Rs 29.77 crores – up from Rs 25.12 crores

RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in PBT by 19% Y-o-Y and by 116% Q-o-Q for Q1 FY24. Revenue from operations at Rs 147.78 crores registered a growth of 15% Y-o-Y and a growth of 25% Q-o-Q for Q1 FY24. The Company maintained an upward trajectory in EBITDA margin, which improved from 22.5% to 23.0% Y-o-Y.

**Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd.** said, “In Q1 FY24, the overall performance of the Company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs. Revenue and PBT grew by 15% and 19% respectively Y-o-Y. EBITDA margin retained its upward trajectory growing from 22.5% to 23.0% Y-o-Y. The Company continues to remain debt-free.

Domestic Formulations business, the biggest contributor to the Company’s business, recorded robust growth both in value and volume - significantly and consistently ahead of the market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth, our new product portfolio comprising of newer and progressive segments is also witnessing an impressive uptake. Our foray into Rheumatology has strengthened our Specialty segment. Our MABs portfolio is continuing to post robust performance. Salesforce productivity continues to register healthy upward momentum.

International Formulations business has also shown robust growth while emerging as another growth driver for the Company, registering healthy growth in both sales and profits. The company is investing in plant modernization and capacity expansion in both plants as well as working on building a healthy product pipeline to accelerate exports. API business continues to register healthy growth. Our relentless focus on achieving cost efficiencies in our operations, and eye on sales hygiene, is helping us to consistently improve our margins. We are well on course to implement our Transformation Agenda to achieve our strategic goals.”

**RPG Life Sciences Ltd ([www.rpglifesciences.com](http://www.rpglifesciences.com)):**

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a research-based pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

**RPG Enterprises ([www.rpggroup.com](http://www.rpggroup.com)):**

RPG Enterprises, established in 1979, is one of India’s fastest-growing business groups with a turnover of US\$ 4.4 Billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses.

**Media Contact:**

Shalini Singh – 92233 36815 | [shalini@rpg.in](mailto:shalini@rpg.in)

Svati Maddur – 99208 87227 | [svati@rpg.in](mailto:svati@rpg.in)

